Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline

Bristol-Myers Squibb (BMY) reported Q2 2025 revenues of $12.3 billion, exceeding expectations and prompting a raise in full-year revenue guidance, though GAAP EPS missed forecasts and non-GAAP EPS guidance was lowered. Despite strong profitability and an attractive valuation with a nearly 6% dividend yield, BMY's stock has significantly underperformed, down 25% year-to-date, reflecting market skepticism over impending patent expiries for key revenue drivers like Eliquis and Opdivo. The company is entering a critical period with numerous upcoming clinical data readouts for its pipeline assets, including CELMoDs and Milvexian, which are essential to demonstrate future growth and justify its valuation amidst these patent challenges and recent executive changes.

Analysis

Bristol-Myers Squibb's Q2 2025 results highlight a significant disconnect between current operational performance and market valuation. The company surpassed revenue expectations with $12.3 billion, raised its full-year revenue forecast to a midpoint of $47 billion, and maintained strong profitability with a 37.5% operating margin. However, this was undermined by a GAAP EPS miss, lowered non-GAAP EPS guidance, and a stock price decline of over 25% year-to-date. This market skepticism is rooted in the firm's acute 'patent cliff' problem; its two largest drugs, Eliquis and Opdivo, contribute over 50% of revenue and face patent expirations in the coming years, with Eliquis's protection potentially ending as early as 2026. Although the 'growth portfolio' now represents 54% of revenue, recent pipeline setbacks have eroded confidence in its ability to offset these losses. Specifically, a failed study for a new form of Opdivo and disappointing trial data for the recently acquired Cobenfy have tempered expectations. Consequently, the company is entering a critical 'data rich' period where upcoming results for assets like the CELMoD platform and Eliquis-successor Milvexian are paramount. The recent change in Chief Medical Officer, coupled with a $46.2 billion long-term debt load, further elevates execution risk, making the currently attractive valuation (forward P/E of ~6.7x, ~6% dividend yield) a bet on a successful, yet unproven, pipeline and operational turnaround.

Key Decisions for Investors

• Consider the stock's low valuation, with a forward P/E of approximately 6.7x and a dividend yield near 6%, but weigh this against the substantial risk from impending patent expirations for key drugs Eliquis and Opdivo.
• Closely monitor the series of upcoming clinical data readouts, as positive results for pipeline assets like the CELMoDs in multiple myeloma and Milvexian are essential to validate the company's future growth narrative.
• The appointment of a new Chief Medical Officer makes near-term pipeline execution a critical performance indicator, and any further clinical setbacks should be viewed as a significant red flag.
• Track the company's deleveraging progress toward its stated goal of paying down $10 billion in debt by mid-2026, as this is critical for financial flexibility during the upcoming revenue trough.